DAP most commonly refers to 3,4-diaminopyridine, a prescription medication used to treat a rare neuromuscular condition called Lambert-Eaton myasthenic syndrome (LEMS). Sold under the brand name Firdapse, it was approved by the FDA in November 2018 for adults and later expanded in 2022 to include children aged 6 and older. The term “DAP” can also refer to Drug Assistance Programs that help people afford medications, particularly for HIV treatment, though the medical drug is the more common search result.
What DAP Treats
Lambert-Eaton myasthenic syndrome is an autoimmune disease where the body’s own antibodies attack calcium channels on nerve endings. These channels are essential for triggering the release of acetylcholine, the chemical messenger that tells your muscles to contract. When those channels are blocked, the signal between nerve and muscle weakens, leading to progressive muscle weakness that typically starts in the legs and hips, making it hard to walk, climb stairs, or stand from a seated position.
LEMS is rare, affecting only a small number of people worldwide, which is why DAP carries an orphan drug designation from the FDA. About half of LEMS cases are associated with an underlying cancer, most often small cell lung cancer. In the other half, the immune system attacks the calcium channels without any cancer trigger.
How DAP Works in the Body
DAP blocks potassium channels on nerve terminals. That might sound unrelated to a calcium channel problem, but the two are closely linked. Normally, after a nerve fires, potassium channels open to reset the nerve ending. By blocking those potassium channels, DAP keeps the nerve ending electrically active for a fraction of a second longer. That extra time allows more calcium to flow in through whatever functional calcium channels remain, which in turn increases the release of acetylcholine. The result is a stronger signal reaching the muscle.
This mechanism makes DAP the primary symptomatic treatment for LEMS. It does not fix the underlying autoimmune problem or cure the disease, but it can meaningfully improve muscle strength and daily function for many patients.
Dosing and What to Expect
Treatment typically starts at a low dose and is gradually increased based on how well you respond and what side effects appear. The maximum recommended daily dose is 50 mg, usually divided into multiple smaller doses taken throughout the day. An average treatment dose in clinical practice is around 60 mg daily, though your doctor will tailor this to your situation.
The most commonly reported side effects include tingling or “pins and needles” sensations, headache, nausea, dizziness, and muscle spasms. Some people experience joint or limb pain, trouble sleeping, diarrhea, or unusual tiredness. Less bothersome effects like back pain, constipation, heartburn, and feeling cold may fade as your body adjusts to the medication. Seizures are a known risk at higher doses, which is why dosing is carefully managed.
Cost of Treatment
DAP is expensive. Annual treatment costs are estimated between $52,000 and $69,000 per patient, depending on the specific formulation and dosage. Because LEMS is so rare and Firdapse holds orphan drug exclusivity (protected through at least late 2025), there is limited price competition. Most patients rely on insurance coverage, manufacturer assistance programs, or specialty pharmacy support to afford the medication.
How LEMS Is Diagnosed
Before a doctor prescribes DAP, LEMS needs to be confirmed through specific nerve conduction testing. The hallmark finding is something called postexercise facilitation: after brief intense muscle use or rapid electrical stimulation, the nerve-to-muscle signal temporarily improves in a dramatic way. A signal increase of 60% or more after stimulation identifies LEMS in about 97% of cases, and this pattern is almost never seen in myasthenia gravis, a more common condition that can look similar on the surface.
Blood tests for antibodies against voltage-gated calcium channels further support the diagnosis. Because of the cancer association, most newly diagnosed LEMS patients also undergo imaging to screen for lung cancer.
DAP as a Drug Assistance Program
In a completely different context, “DAP” sometimes refers to Drug Assistance Programs, most notably the AIDS Drug Assistance Program (ADAP) under the federal Ryan White HIV/AIDS Program. ADAP provides FDA-approved HIV medications to people with limited or no health insurance. The program operates in all 50 states, Washington D.C., and U.S. territories.
Eligibility requires a confirmed HIV diagnosis, residency in the state where you’re applying, and income below a set threshold, often around 400% of the federal poverty level, though each state sets its own cutoff. Beyond covering medications directly, ADAP funds can also be used to purchase health insurance for eligible clients or provide services that help people stick with their treatment plans. Every state program must cover at least one drug from each class of HIV antiretroviral medications on its formulary.